[ CAS No. 27561-62-2 ] {[proInfo.proName]}

Name: 27561-62-2|Cyclohexyl(piperazin-1-yl)methanone|96%
Brand: Ambeed
SKU: A308115
Price: 11.0 USD
Availability: InStock
Rating: 92 (26 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 27561-62-2

Structure of 27561-62-2 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 27561-62-2 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 27561-62-2 ]

SDS Specification

Alternatived Products of [ 27561-62-2 ]

Product Details of [ 27561-62-2 ]

CAS No. :	27561-62-2	MDL No. :	MFCD06798113
Formula :	C₁₁H₂₀N₂O	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	ZSZROXCAFYZNHE-UHFFFAOYSA-N
M.W :	196.29	Pubchem ID :	3437502
Synonyms :

Calculated chemistry of [ 27561-62-2 ]

Physicochemical Properties

Num. heavy atoms :	14
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.91
Num. rotatable bonds :	2
Num. H-bond acceptors :	2.0
Num. H-bond donors :	1.0
Molar Refractivity :	64.49
TPSA :	32.34 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	Yes
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.68 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.36
Log Po/w (XLOGP3) :	1.15
Log Po/w (WLOGP) :	0.24
Log Po/w (MLOGP) :	1.19
Log Po/w (SILICOS-IT) :	1.6
Consensus Log Po/w :	1.31

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.65
Solubility :	4.4 mg/ml ; 0.0224 mol/l
Class :	Very soluble
Log S (Ali) :	-1.42
Solubility :	7.4 mg/ml ; 0.0377 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-1.77
Solubility :	3.36 mg/ml ; 0.0171 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.74

Safety of [ 27561-62-2 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338-P310	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 27561-62-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 27561-62-2 ]
Downstream synthetic route of [ 27561-62-2 ]

[ 27561-62-2 ] Synthesis Path-Upstream 1~1

1
[ 98-89-5 ]
[ 27561-62-2 ]

Reference： [1] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 16, p. 3739 - 3743

[ 27561-62-2 ] Synthesis Path-Downstream 1~27

1
[ 80852-52-4 ]
[ 27561-62-2 ]
Naphthalene-2-sulfonic acid [1-(3-cyano-benzyl)-2-(4-cyclohexanecarbonyl-piperazin-1-yl)-2-oxo-ethyl]-amide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1997,vol. 40,p. 3091 - 3099

2
[ 110-85-0 ]
[ 2719-27-9 ]
Merrifield resin 3-diazophenylether tetrafluoroborate [ No CAS ]
[ 27561-62-2 ]

Reference： [1]Tetrahedron Letters,2004,vol. 45,p. 2839 - 2841

3
[ 61040-81-1 ]
[ 27561-62-2 ]
C₂₁H₃₀N₂O₄ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2007,vol. 15,p. 6649 - 6658

4
[ 685565-10-0 ]
[ 27561-62-2 ]
[ 685871-62-9 ]

Yield	Reaction Conditions	Operation in experiment
		TO 4- (3-PIPERIDIN-1-YLPROPOXY) BENZOYL CHLORIDE HYDROCHLORIDE (D3) (0.24g) in DCM (10 ML) was added 1- (CYCLOHEXANECARBONYL)-PIPERAZINE (0.155 g) and diethylaminomethyl polystyrene (3. 2MMOL/G, 0.69g). The mixture was stirred for 16h. The reaction mixture was then loaded directly onto a silica column and eluted with 0-10% MEOH (containing 10% 0.880 ammonia solution) in DCM. The isolated free base was dissolved in DCM (5ML) and treated with 4N HCI/DIOXANE solution (1 ml) with stirring for 10MIN. The reaction was concentrated, and the residue co-evaporated with toluene (3X10M1) and then dried at 50C under high vacuum for 16h to yield the title compound (E57) as a PALE SOLID (0.165G). MS ELECTROSPRAY (+ION) -442 (MH+). 1H NMR 8 (DMSO-D6): 9.71 (S, 1H), 7.39 (d, 2H, J=6.84Hz), 7.00 (d, 2H, J=6.84Hz), 4.10 (m, 2H), 3.47-3. 25 (m, 10H), 3.16 (m, 2H), 2.90 (m, 2H), 2.55 (m, 1H), 2.19 (m, 2H), 1.82-1. 62 (m, 10H), 1.40-1. 16 (m, 6H).

Reference： [1]Patent: WO2004/37800,2004,A1 .Location in patent: Page 33

5
[ 877842-14-3 ]
[ 27561-62-2 ]
C₂₆H₂₉N₅O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
56%	With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In ISOPROPYLAMIDE;	4-[4-(4-Cyclohexanecarbonyl-piperazine-1-carhonyl)-pyridin-2-ylmethyl-2H-phthalazin-1-one (5)To a stirred solution of 2-(4-oxo-3,4-dihydro-phthalazin-1-ylmethyl)-isonicotinic acid (iva)(0.25g, 0.89mol) in diemthylacetamide (2mL) was added <strong>[27561-62-2]cyclohexyl-piperazin-1-yl-methanone</strong> (0.20g, LOmmol) followed by HBTU (0.38g, LOmmol) and diisopropyl ethyl amine (0.35mL, 20.0 mmol) and stirred. The reaction mixture was then concentrated in vacuo and resulting oil subjected to flash chromatography eluent 9:1 EtOAc / MeOH. (rf of 0.3) The titledcompound was isolated as a white solid. Single peak in LC-MS analysis, (0.18g, 56%); m/z (LC-MS, ESP), RT=4.07mins, (M+H)=460; 1H NMR (300 MHz) 12.57 (1H, S -NH), 8.56 (1H, d, J 5.1 Hz), 8.26 (1H, dd, J 1.5, 8.1Hz), 7.95- 7.80 (3H, m), 7.38 (1H, S), 7.25 (1H, d, J 5.7Hz), 4.51 (2H, S), 3.56-3.17 (8H, m), 2.58 (1H, m), 1.71-1.61 (5H, m), 1.38-1.22 (5H, m).

Reference： [1]Patent: WO2006/21801,2006,A1 .Location in patent: Page/Page column 65; 67-68

6
[ 23680-84-4 ]
[ 27561-62-2 ]
[ 64633-57-4 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 3 4-Amino-2-[4-(cyclohexylcarbonyl)-1-piperazinyl]-6,7-dimethoxyquinazoline <strong>[27561-62-2]N-(Cyclohexylcarbonyl)piperazine</strong> (5.9 g., 0.03 mole) and 2-chloro-4-amino-6,7-dimethoxyquinazoline (7.2 g., 0.03 mole) are reacted according to the procedure of Example 1(a). The crude product crystallized from methanol affords analytically pure 4-amino-2-[4-(cyclohexylcarbonyl)-1-piperazinyl]-6,7-dimethoxyquinazoline, m.p. 223-225 C., resolidifying and remelting at 248.0-250.0 C. (corr.) Analysis. Calcd. for C21 H29 N5 O3 (percent): C, 63.14; H, 7.32; N, 17.53. Found (percent): C, 63.07; H, 7.43; N, 17.63.

Reference： [1]Patent: US4060615,1977,A

7
[ 763114-26-7 ]
[ 27561-62-2 ]
[ 1070772-22-3 ]

Reference： [1]Journal of Medicinal Chemistry,2008,vol. 51,p. 6581 - 6591

8
[ 850172-44-0 ]
[ 27561-62-2 ]
[ 1374567-60-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 3157 - 3162

9
[ 27561-62-2 ]
[ 1374567-75-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 3157 - 3162

10
[ 27561-62-2 ]
[ 1374567-19-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 3157 - 3162

11
[ 50-00-0 ]
[ 7559-81-1 ]
[ 27561-62-2 ]
[ 1428245-56-0 ]

Yield	Reaction Conditions	Operation in experiment
	In methanol; at 20℃;	General procedure: The basic substituent was introduced in the 6th-position of chlorokojic acid via a Mannich-type reaction, using formaline and an appropriate substituted piperidine or piperazine derivatives in methanol at room temperature. The reaction proceeded very rapidly. Mannich bases were prepared by the reaction of substituted piperazine or piperidine derivatives and chlorokojic acid in MeOH with 37% formaline. The mixture was stirred vigorously for 15-25min at room temperature. The resulting precipitate was collected by filtration and washed with cold MeOH. Formation of the desired new Mannich base derivatives were confirmed on the basis of elemental analysis, and the structures of the compounds were supported by spectral data. Chlorokojic acid; Yield 60%, mp: 166-167C. 6-(Chloromethyl)-3-hydroxy-2-((4-(4-iodophenyl)piperazin-1-yl)methyl)-4H-pyran-4-one (Compound 9) C17H18ClIN2O3, yield: 56%; mp: 182-3C; %CHN Found (Calculated): C 44.65 (44.32), H 3.91 (3.94), N 6.61 (6.08); IR nu (cm-1): 1630 (C=O), 1456 (C=C), 1202 (C-O); 1H NMR (DMSO-d6, 400MHz) delta ppm: 2.60 (4H; t; J=4.8; piperazine-H2?, H6?), 3.13 (4H; t; J=4.8; piperazine-H3?,H5?), 3.62 (2H; s; -CH2-), 4.66 (2H; s; ClCH2-), 6.55 (1H; s; H5), 6.76 (2H; d; J=9.2; Ar-H2?, H6?), 7.46 (2H; d; J=9.2; Ar-H3?, H5?), 9.22 (1H; s; -OH); 13C NMR (DMSO, 400MHz) delta ppm: 42.11, 48.35, 52.77, 54.02, 81.32, 113.12, 118.49, 137.93, 144.82, 148.14, 151.19, 161.93, 174.15; ESI-MS (m/z): 399 (100%), 461 (M++H), 463 (M++H+2), 483 (M++Na). Ethyl 4-((6-(chloromethyl)-3-hydroxy-4-oxo-4H-pyran-2-yl)methyl)piperazine-1-carboxylate (Compound 24) C14H19ClN2O5, yield: 63%; mp: 136-7C; %CHN Found (Calculated): C 50.59 (50.84), H 5.63 (5.79), N 8.38 (8.47); IR nu (cm-1): 1679 (C=O), 1424 (C=C), 1220 (C-O); 1H NMR (DMSO-d6, 400MHz) delta ppm: 1.67 (3H; t; J=7.0; -CH3), 2.44 (4H; t; J=5.2; piperazine-H2?, H6?), 3.36 (4H; t; J=5.2; piperazine-H3?,H5?), 3.60 (2H; s; -CH2-), 4.02 (2H; q; J=6.8; -CH2CH3), 4.65 (2H; s; ClCH2-), 6.55 (1H; s; H5), 9.19 (1H; br s; -OH); 13C NMR (DMSO, 400MHz) delta ppm: 15.22, 42.10, 43.93, 52.62, 53.10, 61.39, 113.12, 144.86, 147.90, 155.23, 161.94, 174.16; ESI-MS (m/z): 331 (M++H), 333 (M++H+2), 353 (M++Na, 100%). Benzyl 4-((6-(chloromethyl)-3-hydroxy-4-oxo-4H-pyran-2-yl)methyl)piperazine-1-carboxylate (Compound 25) C19H21ClN2O5, yield: 64%; mp: 141-2C; %CHN Found (Calculated): C 57.86 (58.09), H 5.25 (5.39), N 7.07 (7.13); IR nu (cm-1): 1679 (C=O), 1446 (C=C), 1225 (C-O); 1H NMR (DMSO-d6, 400MHz) delta ppm: 2.45 (4H; t; J=4.8; piperazine-H2?,H6?), 3.40 (4H; m; piperazine-H3?,H5?), 3.60 (2H; s; -CH2-), 4.65 (2H; s; ClCH2-), 5.07 (2H; s; -CH2COO-), 6.55 (1H; s; H5), 7.28-7.38 (5H; m; Ar-H), 9.20 (1H; br s; -OH); 13C NMR (DMSO, 400MHz) delta ppm: 42.10, 44.15, 52.64, 54.01, 66.89, 113.12, 128.20, 128.50, 129.09, 137.57, 144.82, 148.05, 155.05, 161.92, 174.17; ESI-MS (m/z): 393 (M++H), 395 (M++H+2), 415 (M++Na, 100%). 1-((6-(Chloromethyl)-3-hydroxy-4-oxo-4H-pyran-2-yl)methyl)-4-phenylpiperidine-4-carbonitrile (Compound 26) C19H19ClN2O3, yield: 71%; mp: 156-7C; %CHN Found (Calculated): C 64.35 (63.60), H 5.39 (5.34), N 7.91 (7.81); IR nu (cm-1): 1660 (C=O), 1455 (C=C), 1200 (C-O); 1H NMR (DMSO-d6, 400MHz) delta ppm: 1.99-2.56 (8H; m; piperidine); 3.68 (2H; s; -CH2-), 4.66 (2H; s; ClCH2-), 6.56 (1H; s; H5), 7.34-7.54 (5H; m; Ar-H); 9.24 (1H; br s; -OH); 13C NMR (DMSO, 400MHz) delta ppm: 36.15, 42.09, 42.29, 50.69, 54.03, 113.19, 122.67, 126.33, 128.75, 129.71, 140.82, 144.87, 148.19, 161.95, 174.19; ESI-MS (m/z): 381 (100%, M++Na), 359 (M++H), 361 (M++H+2). 6-(Chloromethyl)-3-hydroxy-2-((4-phenyl-5,6-dihydropyridin-1(2H)-yl)methyl)-4H-pyran-4-one (Compound 27) C18H18ClNO3, yield: 76%; mp: 165-6C; %CHN Found (Calculated): C 64.67 (65.16), H 5.33 (5.47), N 4.16 (4.22); IR nu (cm-1): 1622 (C=O), 1456 (C=C), 1198 (C-O); 1H NMR (DMSO-d6, 400MHz) delta ppm: 2.49-3.19 (6H; m; pyridine), 3.69 (2H; s; -CH2-), 4.67 (2H; s; ClCH2-), 6.14 (1H; t; J=3.6; pyridine), 6.55 (1H; s; H5), 7.22-7.42 (5H; m; Ar-H); 13C NMR (DMSO, 400MHz) delta ppm: 27.99, 42.13, 50.20, 52.76, 53.62, 113.13, 122.47, 125.24, 127.69, 129.04, 134.55, 140.75, 144.76, 148.52, 161.94, 174.18; ESI-MS (m/z): 332 (100%, M++H), 334 (M++H+2), 354 (M++Na). 6-(Chloromethyl)-2-((4-(4-chlorophenyl)-5,6-dihydropyridin-1(2H)-yl)methyl)-3-hydroxy-4H-pyran-4-one (Compound 28) C18H17Cl2NO3, yield: 97%; mp: 166-7C; %CHN Found (Calculated): C 59.15 (59.03), H 4.61 (4.68), N 4.01 (3.82); IR nu (cm-1): 1631 (C=O), 1458 (C=C), 1194 (C-O); 1H NMR (DMSO-d6, 400MHz) delta ppm: 2.47-3.27 (6H; m; pyridine), 3.69 (2H; s; -CH2-), 4.66 (2H; s; ClCH2-), 6.18 (1H; br s; pyridine), 6.55 (1H; s; H5), 7.36 (2H; d; J=8.4; Ar-H2?, H6?), 7.44 (2H; d; J=8.4; Ar-H3?, H5?); 13C NMR (DMSO, 400MHz) delta ppm: 27.86, 42.13, 50.08, 52.70, 53.55, 113.13, 123.38, 127.02, 128.92, 132.19, 133.46, 139.54, 144.76, 148.47, 161.94, 174.17; ESI-MS (m/z): 218 (100%), 366 (M++H), 368 (M++H+2), 388 (M++Na). 6-(Chloromethyl)-2-((4-(4-fluorophe...

Reference： [1]Journal of Enzyme Inhibition and Medicinal Chemistry,2013,vol. 28,p. 627 - 638
[2]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 3646 - 3649

12
[ 1259916-28-3 ]
[ 27561-62-2 ]
[ 1259917-85-5 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium carbonate; sodium iodide; at 150℃; for 1h;Microwave irradiation;	General procedure: 5.1.5. General procedure 4 (GP4) A halide intermediate (1.0equiv), amine (0.9-10equiv) and optionally a base (2.7equiv) and halogenating agent (0.5equiv) were mixed together in industrial methylated spirits (15mL per g halide) and heated in a microwave at 150C for 1h, repeating if neccesary. Upon completion of the reaction, the mixture was passed through a phase seperation cartridge, concentrated and purified

Reference： [1]Bioorganic and Medicinal Chemistry,2013,vol. 21,p. 3334 - 3347

13
[ 1259915-95-1 ]
[ 27561-62-2 ]
[ 1259917-49-1 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium carbonate; at 150℃; for 1h;Microwave irradiation;	General procedure: 5.1.5. General procedure 4 (GP4) A halide intermediate (1.0equiv), amine (0.9-10equiv) and optionally a base (2.7equiv) and halogenating agent (0.5equiv) were mixed together in industrial methylated spirits (15mL per g halide) and heated in a microwave at 150C for 1h, repeating if neccesary. Upon completion of the reaction, the mixture was passed through a phase seperation cartridge, concentrated and purified

Reference： [1]Bioorganic and Medicinal Chemistry,2013,vol. 21,p. 3334 - 3347

14
[ 27561-62-2 ]
[ 1594853-48-1 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 1830 - 1838
[2]Bioorganic and Medicinal Chemistry Letters,2015,vol. 24,p. 1830 - 1838

15
[ 27561-62-2 ]
[ 1154693-71-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 1830 - 1838
[2]Bioorganic and Medicinal Chemistry Letters,2015,vol. 24,p. 1830 - 1838

16
[ 636-98-6 ]
[ 27561-62-2 ]
[ 424819-33-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 1830 - 1838
[2]Bioorganic and Medicinal Chemistry Letters,2015,vol. 24,p. 1830 - 1838

17
[ 1622867-34-8 ]
[ 27561-62-2 ]
[ 1622867-02-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 3739 - 3743

18
[ 98-89-5 ]
[ 27561-62-2 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 3739 - 3743

19
4-Cyclohexanecarbonyl-piperazine-1-carboxylic acid tert-butyl ester [ No CAS ]
[ 27561-62-2 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 3739 - 3743

20
[ 619-45-4 ]
[ 27561-62-2 ]
C₁₉H₂₆N₄O₃ [ No CAS ]

Reference： [1]Canadian Journal of Chemistry,2014,vol. 92,p. 838 - 848

21
[ 873-74-5 ]
[ 27561-62-2 ]
C₁₈H₂₃N₅O [ No CAS ]

Reference： [1]Canadian Journal of Chemistry,2014,vol. 92,p. 838 - 848

22
4-((1-crboxypentyl)oxy)-2-hydroxy-5-((4-(phenoxymethyl)phenyl)ethynyl)benzoic acid [ No CAS ]
[ 27561-62-2 ]
C₃₉H₄₄N₂O₇ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 2798 - 2809

23
2-oxo-2-((4-((2-phenyl-2-sulfoacetamido)methyl)phenyl)amino)acetic acid [ No CAS ]
[ 27561-62-2 ]
C₂₈H₃₄N₄O₇S [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 782 - 786

24
2-(2-bromoethyl)-2,4-dihydro-7-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole [ No CAS ]
[ 27561-62-2 ]
2-[2-(4-cyclohexylcarbonylpiperazinyl)ethyl]-2,4-dihydro-7-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1840 - 1853

25
[ 27561-62-2 ]
[ 220696-97-9 ]
(4-([1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-yl)piperazin-1-yl)(cyclohexyl)methanone [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
65%	In ethyl acetate; at 20 - 60℃;	General procedure: The mixture of compound 3 (1g, 4.6mmol) and 95% ethanol (30ml) was added to morpholine (0.4g, 4.6mmol).The mixture was stirred at room temperature for 30min, then warmed up to 60C. After the starting 3 was completely consumed (the reaction courses was monitored by TLC), evaporation of the ethanol, the crude yellow compound 4j was obtained and purified by preparative thin-layer chromatography over silica gel PF 254 (2mm, ethyl acetate: petroleum ether=1:1). Yield: 78%.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 3042 - 3047

26
C₁₀H₇ClO₂S*(x)ClH [ No CAS ]
[ 27561-62-2 ]
cyclohexyl[4-(naphthalene-1-sulfonyl)piperazin-1-yl]methanone [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In ethyl acetate; at 20℃;	General procedure: 10mM sulfochloride hydrochloride was suspendedin 50 ml ethylacetate and 11mM amine component wasadded with stirring. 2.8 ml triethylamine dissolved in 10 ml ethylacetatewas dropped in with stirring and kept stirring overnight atambient temperature. The reaction mixture was extracted threetimes with water, the organic phase was dried over sodium sulfatefiltered, and then evaporated to dryness. For cases in which an oilyproduct was obtained, the residue was treated with diisopropylether.

Reference： [1]European Journal of Medicinal Chemistry,2019,vol. 174,p. 309 - 329

27
C₁₀H₇ClO₂S*(x)ClH [ No CAS ]
[ 27561-62-2 ]
cyclohexyl[4-(naphthalene-2-sulfonyl)piperazin-1-yl]methanone [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In ethyl acetate; at 20℃;	General procedure: 10mM sulfochloride hydrochloride was suspendedin 50 ml ethylacetate and 11mM amine component wasadded with stirring. 2.8 ml triethylamine dissolved in 10 ml ethylacetatewas dropped in with stirring and kept stirring overnight atambient temperature. The reaction mixture was extracted threetimes with water, the organic phase was dried over sodium sulfatefiltered, and then evaporated to dryness. For cases in which an oilyproduct was obtained, the residue was treated with diisopropylether.

Reference： [1]European Journal of Medicinal Chemistry,2019,vol. 174,p. 309 - 329

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 27561-62-2 ]

Amides

[ 59878-57-8 ]

1-(Cyclopropylcarbonyl)piperazine

Similarity: 0.89

[ 1005-85-2 ]

2-Azaspiro[4.5]decan-1-one

Similarity: 0.84

[ 39711-79-0 ]

N-Ethyl-2-isopropyl-5-methylcyclohexanecarboxamide

Similarity: 0.83

[ 64744-50-9 ]

2-Azaspiro[4.5]decan-3-one

Similarity: 0.81

[ 35090-94-9 ]

Piperidin-3-yl(pyrrolidin-1-yl)methanone

Similarity: 0.80

Related Parent Nucleus of
[ 27561-62-2 ]

Aliphatic Heterocycles

[ 1005-85-2 ]

2-Azaspiro[4.5]decan-1-one

Similarity: 0.84

[ 64744-50-9 ]

2-Azaspiro[4.5]decan-3-one

Similarity: 0.81

[ 1956325-48-6 ]

(3-Aminoazetidin-1-yl)(cyclopropyl)methanone hydrochloride

Similarity: 0.80

[ 35090-94-9 ]

Piperidin-3-yl(pyrrolidin-1-yl)methanone

Similarity: 0.80

[ 7506-66-3 ]

cis-Hexahydro-1H-isoindole-1,3(2H)-dione

Similarity: 0.79

Piperazines

[ 59878-57-8 ]

1-(Cyclopropylcarbonyl)piperazine

Similarity: 0.89

[ 909409-91-2 ]

(R)-2,2-Dimethyl-1-(3-methylpiperazin-1-yl)propan-1-one

Similarity: 0.79

[ 143673-66-9 ]

(R)-3-Isopropylpiperazine-2,5-dione

Similarity: 0.70

[ 14771-77-8 ]

3-Isopropylpiperazine-2,5-dione

Similarity: 0.70

[ 1638137-85-5 ]

(S)-1-(3-Methylpiperazin-1-yl)ethanone hydrochloride

Similarity: 0.64

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 27561-62-2 ] {[proInfo.proName]}

Quality Control of [ 27561-62-2 ]

Related Doc. of [ 27561-62-2 ]

Product Details of [ 27561-62-2 ]

Calculated chemistry of [ 27561-62-2 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 27561-62-2 ]

Application In Synthesis of [ 27561-62-2 ]

[ 27561-62-2 ] Synthesis Path-Upstream 1~1

[ 27561-62-2 ] Synthesis Path-Downstream 1~27

Related Functional Groups of [ 27561-62-2 ]

Amides

Related Parent Nucleus of [ 27561-62-2 ]

Aliphatic Heterocycles

Piperazines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 27561-62-2 ]

Related Parent Nucleus of
[ 27561-62-2 ]